Equity Field Notes from temporal sources

[DanWebzster]

OMER is a non-specialized smallcap pharma trying to build a pipeline of first-in-class therapeutics

It markets its lead produc and manages a pipeline of 7 other candidates

Narsoplimab is the lead pipeline candidate. It's a human monoclonal antibody that effects one discrete pathway of the complement immune system while leaving other pathways of innate immunity in tact.

N-mab is an FDA breakthrough therapy with 4 indications in the clinic. On 3/3/20 N-mab had a very encouraging readout in the lead indication and will receive priority review once the BLA is submitted in Q3/20.

Two other indications are in Ph3 and another is in Ph2 testing.

MC = ~800M
On 3/31/20 Cash was 53.9M. Burn rate is in excess of 20M/Q

OMER is likely to raise capital in 2020.

Wait for dilution before considering buying this stock for a run-up into an FDA decision on Narsoplimab.